Hengyou Weng

Hengyou Weng

Auto-generated profile, based on publicly available information

Hengyou Weng

The First Affiliated Hospital, The Fifth Affiliated Hospital, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510005, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2020 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CZChengwu Zeng
Chengwu Zeng
WHWanxu Huang
Wanxu Huang
YLYangqiu Li
Yangqiu Li
HWHengyou Weng
Hengyou Weng
N6-methyladenosine (m6A) is the most abundant mRNA modification and is catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is the sole catalytic subunit. Accumulating evidence in recent years reveals that METTL3 plays key roles in a variety of cancer types, either dependent or independent on its m6A RNA methyltransferase activity. While the roles of m6A modifications in cancer have been extensively reviewed elsewhere, the critical functions of METTL3 in various types of cancer, as well as the potential targeting of METTL3 as cancer treatment, have not yet been highlighted. Here we summarize our current understanding both on the oncogenic and tumor-suppressive functions of METTL3, as well as the underlying molecular mechanisms. The well-documented protein structure of the METTL3/METTL14 heterodimer provides the basis for potential therapeutic targeting, which is also discussed in this review.

27 October 2022 in Cancer Cell
Verified
Journal Article
Closed access
HWHengyou Weng
Hengyou Weng
FHFeng Huang
Feng Huang
ZYZhaojin Yu
Zhaojin Yu
ZCZhenhua Chen
Zhenhua Chen
EPEmily Prince
Emily Prince
JCJianjun Chen
Jianjun Chen

6 November 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
SZSubo Zhang
Subo Zhang
FHFeng Huang
Feng Huang
YWYushuai Wang
Yushuai Wang
YLYifei Long
Yifei Long
YLYuanpei Li
Yuanpei Li
HHHuilin Huang
Huilin Huang
RNA modification has emerged as an important epigenetic mechanism that controls abnormal metabolism and growth in acute myeloid leukaemia (AML). However, the roles of RNA N4-acetylcytidine (ac4C) modification in AML remain elusive. Here, we report that ac4C and its catalytic enzyme NAT10 drive leukaemogenesis and sustain self-renewal of leukaemic stem cells/leukaemia-initiating cells through reprogramming serine metabolism. Mechanistically, NAT10 facilitates exogenous serine uptake and de novo biosynthesis through ac4C-mediated translation enhancement of the serine transporter SLC1A4 and the transcription regulators HOXA9 and MENIN that activate transcription of serine synthesis pathway genes. We further characterize fludarabine as an inhibitor of NAT10 and demonstrate that pharmacological inhibition of NAT10 targets serine metabolic vulnerability, triggering substantial anti-leukaemia effects both in vitro and in vivo. Collectively, our study demonstrates the functional importance of ac4C and NAT10 in metabolism control and leukaemogenesis, providing insights into the potential of targeting NAT10 for AML therapy.

6 May 2021 in Cancer Communications
Verified
Journal Article
Open access
PDF file
SDShenghua Dong
Shenghua Dong
YWYutong Wu
Yutong Wu
YLYadi Liu
Yadi Liu
HWHengyou Weng
Hengyou Weng
HHHuilin Huang
Huilin Huang
As one of the most studied ribonucleic acid (RNA) modifications in eukaryotes, N 6 ‐methyladenosine (m 6 A) has been shown to play a predominant role in controlling gene expression and influence physiological and pathological processes such as oncogenesis and tumor progression. Writer and eraser proteins, acting opposite to deposit and remove m 6 A epigenetic marks, respectively, shape the cellular m 6 A landscape, while reader proteins preferentially recognize m 6 A modifications and mediate fate decision of the methylated RNAs, including RNA synthesis, splicing, exportation, translation, and stability. Therefore, RNA metabolism in cells is greatly influenced by these three classes of m 6 A regulators. Aberrant expression of m 6 A regulators has been widely reported in various types of cancer, leading to cancer initiation, progression, and drug resistance. The close links between m 6 A and cancer shed light on the potential use of m 6 A methylation and its regulators as prognostic biomarkers and drug targets for cancer therapy. Given the notable effects of m 6 A in reversing chemoresistance and enhancing immune therapy, it is a promising target for combined therapy. Herein, we summarize the recent discoveries on m 6 A and its regulators, emphasizing their influences on RNA metabolism, their dysregulation and impacts in diverse malignancies, and discuss the clinical implications of m 6 A modification in cancer.

6 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FHFeng Huang
Feng Huang
YWYushuai Wang
Yushuai Wang
XZXiuxin Zhang
Xiuxin Zhang
WGWeiwei Gao
Weiwei Gao
JLJingwen Li
Jingwen Li
HWHengyou Weng
Hengyou Weng
Metabolic reprogramming of amino acids represents a vulnerability in cancer cells, yet the mechanisms underlying serine metabolism in acute myeloid leukemia (AML) and leukemia stem/initiating cells (LSCs/LICs) remain unclear. Here, we identify RNA N6-methyladenosine (m6A) modification as a key regulator of serine biosynthesis in AML. Using a CRISPR/Cas9 screen, we find that depletion of m6A regulators IGF2BP3 or METTL14 sensitizes AML cells to serine and glycine (SG) deprivation. IGF2BP3 recognizies m6A on mRNAs of key serine synthesis pathway (SSP) genes (e.g., ATF4, PHGDH, PSAT1), stabilizing these transcripts and sustaining serine production to meet the high metabolic demand of AML cells and LSCs/LICs. IGF2BP3 silencing combined with dietary SG restriction potently inhibits AML in vitro and in vivo, while its deletion spares normal hematopoiesis. Our findings reveal the critical role of m6A modification in the serine metabolic vulnerability of AML and highlight the IGF2BP3/m6A/SSP axis as a promising therapeutic target.

21 May 2024 in Current Opinion in Genetics & Development
Verified
Journal Article
Open access
YWYushuai Wang
Yushuai Wang
HHHuilin Huang
Huilin Huang
JCJianjun Chen
Jianjun Chen
HWHengyou Weng
Hengyou Weng
N6-methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotic messenger RNAs (mRNAs), regulating gene expression at the transcription and post-transcription levels. Complex interplay between m6A and other well-studied epigenetic modifications, including histone modifications and DNA modification, has been extensively reported in recent years. The crosstalk between RNA m6A modification and histone/DNA modifications plays a critical role in establishing the chromatin state for the precise and specific fine-tuning of gene expression and undoubtedly has profound impacts on both physiological and pathological processes. In this review, we discuss the crosstalk between RNA m6A modification and histone/DNA modifications, emphasizing their sophisticated communications and the mechanisms underlying to gain a comprehensive view of the biological relevance of m6A-based epigenetic network.